Chemical Property of 5-(4-cyanophenoxy)-2,3-dihydro-1-hydroxy-2,1-benzoxaborole
Chemical Property:
- Boiling Point:425.9±55.0 °C(Predicted)
- PKA:7.00±0.20(Predicted)
- PSA：62.48000
- Density:1.33±0.1 g/cm3(Predicted)
- LogP:1.56828
- Storage Temp.:room temp
- Solubility.:DMSO (Slightly), Methanol (Slightly)
- Purity/Quality:
-
99% *data from raw suppliers
Crisaborole *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
SDS file from LookChem
Useful:
-
Description
Crisaborole is a phosphodiesterase-
4 (PDE4) inhibitor that was approved by the USFDA for
the treatment of mild to moderate atopic dermatitis (AD) in
patients aged two years and older. The drug, which was
developed by Anacor Pharmaceuticals and later acquired and
marketed by Pfizer, is delivered as a 2% ointment, which is applied topically. The unique employment of boron within
the chemical structure of the drug is designed to enable
selective engagement of PDE4 (an enzyme involved in the
conversion of cAMP into AMP, which signals for downstream
inflammatory events), effective penetration of the drug through
human skin, and rapid clearance to limit systemic circulation. AN2728 is a boron-based, topical anti-inflammatory agent that inhibits phosphodiesterase 4 (PDE4; IC50 = 0.11 μM). It is less potent against PDE1A, PDE3A, and PDE7A (IC50s = 6.12, 6.41, and 0.73 μM, respectively). AN2728 suppresses the release of the proinflammatory cytokines TNF-α, IL-2, INF-γ, IL-5, and IL-10 with IC50 values of 0.50, 0.59, 0.72, 2.25, and 2.58 μM, respectively.
-
Uses
A series of phenoxy benzoxaboroles were synthesized and screened for their inhibitory activity against PDE4 and cytokine release. 5-?(4-?Cyanophenoxy)?-?2,?3-?dihydro-?1-?hydroxy-?2,?1-?benzoxaborole (AN2728) showed potent activity both in vitro and in vivo. AN2728 is being studied as an anti-inflammatory agent.
